Saini M.D.,  Sarbjit

Sainiweb

Johns Hopkins University School of Medicine

Department of Medicine

Division of Allergy & Clinical Immunology

Johns Hopkins Asthma & Allergy Center

5501 Hopkins Bayview Circle, Rm. 2B.71B

Baltimore, MD 21224-6801

Tel:  410-550-2129

Fax:  410-550-2527

Email: ssaini@jhmi.edu


 

Biography:

Sarbjit S. Saini, MD, is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Saini is a diplomate of the American Board of Allergy and Immunology and a fellow of the American Academy of Allergy, Asthma & Immunology.  He is the currently the training program director for the allergy and clinical immunology fellowship program at Johns Hopkins.

 

After earning a medical degree from The Ohio State University College of Medicine, Dr. Saini completed an internship and residency in internal medicine at the University of Michigan Hospitals. He subsequently completed a clinical fellowship in allergy and immunology at the Johns Hopkins University School of Medicine and joined the faculty in 1997.  

 

He has published over 60 articles in peer-reviewed journals such as the Journal of Allergy and Clinical Immunology, the Journal of Immunology, and the Journal of Investigative Dermatology. Dr. Saini has also been a reviewer for the Journal of Allergy and Clinical Immunology, Annals of Internal Medicine, and the Journal of the American Academy of Dermatology. He is has served as an Associate Editor for Allergy, Journal of Investigative Dermatology and for the urticaria and angioedema section for UpToDate.

 

Clinical Interest:

Dr. Saini has an interest in allergic disorders such as allergic rhinitis, asthma, atopic dermatitis, and mast cell disorders such as anaphylaxis. His special interest is in urticaria and angioedema.

 

Research Interest:

Dr. Saini’s research interests have focused on IgE receptor biology and IgE receptor mediated activation of blood basophils and mast cells. Dr. Saini has served as the principal investigator and co-investigator for basic and translational studies examining the role of IgE receptor expression and activation in allergic airways disease, anaphylaxis and chronic urticaria. His research has been supported by the NIH, American Lung Association, and the AAAAI.

 

 

Current Research:

Dr. Saini’s current research interests have focused mechanisms of diease in allergic asthma, allergic rhinitis and also translational studies in chronic idiopathic urticaria.

 

Selected Publications:

 

1) Saini SS, MacGlashan DW Jr, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999; 162: 5624-30

 

2) Saini SS, Klion AD, Holland SM,. Hamilton, RG, Bochner BS, MacGlashan, D.  The relationship between serum IgE and surface levels of FcεR levels on human leukocytes in various diseases: Correlation of expression with FcεRI on basophils but not monocytes or eosinophils. J Allergy Clin Immunol. 2000; 106:514-20

3) Saini SS, Richardson JJ, Wofsy C, Lavens-Phillips, S, Bochner, BS, MacGlashan DW. Jr. Expression and Modulation of FcεRIα and FcεRIb in human blood basophils. J Allergy Clin Immunol. 2001; 107: 832-41

4) Saini SS and MacGlashan D.  How IgE upregulates the allergic response. Curr Opin Immunol. 2002; 14: 694-7

5) Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol. 2004; 114: 527-30

 

6) Saini S, Bloom DC, Bieneman A, Vasagar K, Togias A, Schroeder J. Systemic effects of allergen exposure on blood basophil IL-13 secretion and FcεRIb. J Allergy Clin Immunol. 2004; 114: 768-74

 

7) Schroeder JT, Bieneman AP, Xiao H, Chichester KL, Vasagar K, Saini S, Liu MC. Toll-like receptor 9- and FcεRI-mediated responses in human plasmacytoid DC oppose one another by down regulating receptor expression. J Immunol. 2005; 75: 5724-31

 

8)  Vasagar K, Vonakis BM, Gober LM, Viksman A, Gibbons SP, Saini SS. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy.2006;36:770-6.

 

9) Vonakis BV, Vasagar K, Gibbons SP Jr, Gober L, Sterba PM, Chang H, Saini SS. Basophil FcεRI histamine release parallels expression of SH2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007; 119: 441-8

 

10) Gober LM, Eckman JA, Sterba, PM, Vasagar K, Schroeder JT, Golden D, Saini SS. Expression of activation markers on basophils in a controlled model of anaphylaxis. J Allergy Clin Immunol. 2007; 119: 1181-8

 

11) Eckman JA, Hamilton RG, Gober LM, Sterba PM, Saini SS.  Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol, 2008; 128(8): 1956-63.

 

12) Vonakis, BM and Saini, SS.New concepts in chronic urticaria.  Curr Opin Immunol. 2008, 20(6): 709-16.

 

13) DeLong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect healthcare costs of chronic idiopathic urticaria: a cost analysis of fifty non-immunosuppressed patients. Arch Dermatol. 2008; 144 (1): 35-39.

 

14) Hamilton RG, MacGlashan DW, Jr., Saini, SS. IgE antibody specific activity in human allergic disease. Immunol Res. 2010 (47): 273-284.

 

15) Eckman JA, Sterba PM, Kelly D, Alexander V, Liu, MC, Bochner BS, MacGlashan DW, Jr., Saini, SS. l. Effect of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol.2010, 125 (4): 889-895.

16) Paterniti M, Kelly DC, Eckman JA, Sterba PM, Hamilton RG, Bochner BS, MacGlashan DW, Saini SS. Cat allergen induced blood basophil reactivity in vitro predicts human nasal allergen challenge responses in vivo. Clin Exp Allergy, 2011(7): 963-9.

17) Saini S, Rosen,KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector, S, Maurer, M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011,128(3); 567-573.

 

18) Macglashan DW Jr, Savage J, Wood R, Saini S. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol. 2012 Jul 14. [Epub]

 

19) Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Eng J Med. 2013; 368: 924-35.

 

20) Macglashan DW Jr Saini SS. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol. 2013

 

Mentor List:

 

2004               Rosalyn Baker, M.D., M.H.S.,

 

 

2005               Nkiruka U. Ohajame, M.D.

Present: Assistant Professor, Johns Hopkins Asthma and Allergy Center

 

2005-2007     Laura Gober, M.D.,

Research Fellow, Johns Hopkins University

Present: Attending Physician, Children’s Hospital of Philadelphia

 

2009               Saitu Parihar, Ohio State University, BS, Molecular Genetics,

                        Present: PhD student, University of Maryland   

 

2006-2009    John Eckman, M.D., Clinical Fellow in Allergy/Immunology, Johns Hopkins University

 

2008               Lora Bankova, M.D., Resident

                         Present:  Fellow in Immunology, Brigham and Women’s Hospital

 

2009-2012    Miya Paterniti, M.D.,Clinical Fellow in Allergy/Immunology, Johns Hopkins University

Present: Food and Drug Adminstration

 

2011-12         Emily McGowan, M.D., Clinical Fellow in Allergy/Immunology, Johns Hopkins Division of Allergy & Clinical Immunology

 

2012-             Eric Oliver, M.D.,Clinical Fellow in Allergy/Immunology, Johns Hopkins University



Other: 

For any lab related matters please contact Patricia Meghan Sterba , 410-550-6267

 

 


Updated 9/22/12

COPYRIGHT 2013 JHU SOM DIVISION OF ALLERGY AND CLINICAL IMMUNOLOGY